U
NKTR icon

UBS’s Nektar Therapeutics NKTR Stock Holding History

UBS’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-40
Closed -$8K – 10607
2014
Q2 		$8K Sell
40
-27
-40% -$4.78K ﹤0.01% 9102
2014
Q1 		$12K Sell
67
-2,946
-98% -$583K ﹤0.01% 8694
2013
Q4 		$513K Buy
3,013
+2,846
+1,704% +$459K ﹤0.01% 4308
2013
Q3 		$26K Buy
+167
New +$30.9K ﹤0.01% 7716

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's NKTR Position: Q3 2014 in Review

UBS reduced its Nektar Therapeutics (NKTR) stake by 7.2% in Q3 2014, selling an estimated $25.1K and leaving 1,698 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #4749.

UBS first reported a position in NKTR in Q2 2013 and has held it in 6 quarters since. The position peaked at $772K in Q4 2013. 145 funds tracked by Wall St. Rank hold NKTR as of Q3 2014.

  • UBS held 1,698 shares of Nektar Therapeutics worth $307K as of Q3 2014.
  • UBS sold 131 Nektar Therapeutics shares in Q3 2014, an estimated $25.1K.
  • Nektar Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4749 holding.
  • UBS first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Nektar Therapeutics position peaked at $772K in Q4 2013.
  • 145 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.